JUNIOR STRENGTH ADVIL (ibuprofen) by GSK is cyclooxygenase inhibitors [moa]. First approved in 1996.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
Junior Strength Advil is an oral tablet formulation of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase enzymes to reduce pain and inflammation. It is indicated for fever and pain relief in pediatric and junior populations. The product represents a cornerstone OTC pain management option for families.
As LOE approaches, brand teams face competitive pressure (30/100) and declining market exclusivity, signaling consolidation and shift toward line extension or repositioning roles.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension
Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain
Efficacy and Safety of S (+) - Ibuprofen in the Treatment of Mechanical Low Back Pain
Postoperative Analgesic Effects of Ibuprofen Versus Ketorolac in Patients Undergoing in Orthopedic Surgery
Ibuprofen Plus Acetaminophen for Enhanced Pain Reduction
Worked on JUNIOR STRENGTH ADVIL at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Junior Strength Advil offers experience in OTC brand management, consumer marketing, and retail channel strategy in a mature, high-volume market. However, zero linked job openings and approaching LOE signal limited growth opportunity; career advancement would require transition to growth-stage products or lateral moves into portfolio strategy.